# Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

Study · id `cardio:ct-nct05380063` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05380063](<https://clinicaltrials.gov/study/NCT05380063>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05380063

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2300 participants.

## Technical summary

Registry record NCT05380063. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-14 (actual); primary completion 2025-07-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2300 participants (enrolled count; ClinicalTrials.gov record NCT05380063, source copy `cardio:ctgov-nct05380063-2025-08-27`, retrieved 2026-10-26)
- Started: 2023-02-14 (actual) (ClinicalTrials.gov record NCT05380063, source copy `cardio:ctgov-nct05380063-2025-08-27`, retrieved 2026-10-26)
- Primary completion: 2025-07-08 (actual) (ClinicalTrials.gov record NCT05380063, source copy `cardio:ctgov-nct05380063-2025-08-27`, retrieved 2026-10-26)
- Completion: 2025-07-10 (actual) (ClinicalTrials.gov record NCT05380063, source copy `cardio:ctgov-nct05380063-2025-08-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05380063, source copy `cardio:ctgov-nct05380063-2025-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05380063-2025-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
- Acronym: TOP-CABG
- Condition: Coronary Artery Disease
- Condition: Coronary Artery Bypass Grafting
- Condition: Dual Antiplatelet Therapy
- Condition: Bleeding
- Condition: Myocardial Infarction
- Condition: Myocardial Ischemia
- Condition: Angina Pectoris
- Intervention (Drug): De-escalated Dual Antiplatelet Therapy
- Intervention (Drug): Dual Antiplatelet Therapy
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Angina pectoris (`cardio:angina-pectoris`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial (`cardio:pubmed-42120081`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0ba01d0f53465f01080fe724d161bd47bd56b3e968c46fe75c05490308908ecc
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
